Tyler J. Wilhite, MD, discussed scaling low-dose radiation therapy for osteoarthritis from 1 patient to nearly 20 centers and the referral work behind it.
|Articles|January 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 1
- Volume 4
- Issue 1
Rhône-Poulenc Forms Network To Develop Gene and Cell Therapies
COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc. (Paris, France) has formed a new division, RPR Gencell, dedicated to the discovery, development, and commercialization of cell and gene therapy products. To accelerate such discoveries, the company has also created a biotechnology network comprising 14 biotech companies and academic research centers.
Advertisement
COLLEGEVILLE, Pa--Rhône-Poulenc Rorer Inc. (Paris, France)has formed a new division, RPR Gencell, dedicated to the discovery,development, and commercialization of cell and gene therapy products.To accelerate such discoveries, the company has also created abiotechnology network comprising 14 biotech companies and academicresearch centers.
The US members of the collaboration are Genetix Pharmaceuticals(New York City), The Lawrence Berkeley Laboratory Human GenomeCenter (Berkeley, Calif), Applied Immune Sciences, Inc. (SantaClara, Calif), Darwin Molecular Corporation (Seattle), and IntrogenTherapeutics, Inc. (Houston).
The other network members are French, including the Centre Nationalde Recherche Scientifique (CNRS), the Institut Gustave Roussy,and the Université Louis Pasteur.
Articles in this issue
almost 32 years ago
MDs Fear Managed Care Equals Lower-Quality Carealmost 32 years ago
Dallas Medical Center Launches Umbilical Stem Cell Projectalmost 32 years ago
Navelbine Receives FDA Approval for Advanced Non-Small -Cell Lung Canceralmost 32 years ago
Ethyol Approved for Use in the UKalmost 32 years ago
Success of Breast Conserving Surgery Is Not Diminished in Community Settingalmost 32 years ago
Assessment Tools Are Essential to Improve Management of Painalmost 32 years ago
Undertreating Pain Costs Money in the Long Run, Physician Warnsalmost 32 years ago
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCIalmost 32 years ago
EORTC Endometrial Ca Trial Challenges Findings From GOGAdvertisement
Related to this article
Joshua Richter, MD, and Marco Davila, MD, PhD, discuss early evaluation, sequencing, referral partnerships, and access to CAR T-cell therapy in myeloma.
Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.
In a retrospective study, high AI-derived whole-body tumor volume on PSMA PET-CT was associated with a 3.20-fold higher risk of death in prostate cancer.
The FDA set a June 15, 2027, target action date for sacituzumab tirumotecan in endometrial cancer previously treated with platinum chemotherapy and immunotherapy.
Parul N. Barry, MD, FACRO, discussed building programs early in a career and used low-dose radiotherapy and aromatase inhibitor tolerance to show how to demonstrate value.
Sunnie Kim, MD, outlined how she monitors for endocrine, renal, pulmonary, and other immune-related adverse events during adjuvant durvalumab.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
Sac-TMT Earns FDA Priority Review in Pretreated Endometrial Cancer
3
Scaling Low-Dose Radiation Therapy for Osteoarthritis Across a Network
4
Mapping Practical Steps to Expand CAR T-Cell Access in Multiple Myeloma
5